Caring for adults with pediatric liver disease

Current Gastroenterology Reports

Volumn 11, Issue 1, 2009, Pages 83-89

  Rook, Michelle ^b   Rosenthal, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN GLUCURONIDE; COLESTYRAMINE; GAMMA GLUTAMYLTRANSFERASE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JAGGED1; METFORMIN; PREDNISOLONE; RIMONABANT; TAUROURSODEOXYCHOLIC ACID; TETRAHYDROLIPSTATIN;

ALAGILLE SYNDROME; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILE DUCT ATRESIA; BLOOD CELL COUNT; CHOLANGITIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HEALTH CARE SYSTEM; HEREDITY; HUMAN; INCIDENCE; INTRAHEPATIC CHOLESTASIS; LABORATORY TEST; LIVER DISEASE; LIVER TOXICITY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PHENOTYPIC VARIATION; PORTAL HYPERTENSION; PSYCHOSOCIAL CARE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THYROID FUNCTION TEST; URINALYSIS; VACCINATION;

ADULT; ALAGILLE SYNDROME; BILIARY ATRESIA; CHOLESTASIS, INTRAHEPATIC; CONTINUITY OF PATIENT CARE; FATTY LIVER; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER DISEASES;

EID: 58849119535     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0013-7     Document Type: Review

References (39)

1. Bassett M, Rurray K: Biliary atresia: recent progress. J Clin Gastroenterol 2008, 42: 720-729.
2. Roach J, Bruny J: Advances in the understanding and treatment of biliary atresia. Curr Opin Pediatr 2008, 20: 315-319.
3. Fischler B, Haglund B, Hjern A: A population-based study on the incidence and possible pre- and perinatal etiologic risk factors of biliary atresia. J Pediatr 2002, 141: 217-222.
4. Hung PY, Chen CC, Chen WJ, et al.: Long-term prognosis of patients with biliary atresia: A 25 year summary. J Pediatr Gastroenterol Nutr 2006, 42: 190-195.
5. Poddar U, Bhattacharya A, Thapa BR, et al.: Ursodeoxycholic acid-augmented hepatobiliary scintigraphy in the evaluation of neonatal jaundice. J Nucl Med 2004, 45: 1488-1492.
6. Kahn E: Biliary atresia revisited. Pediatr Dev Pathol 2004, 7: 109-124.
7. Okazaki T, Kobayashi H, Yamataka A, et al.: Long-term postsurgical outcome of biliary atresia. J Pediatr Surg 1999, 34: 312-315.
8. Carceller A, Blanchard H, Alvarez F, et al.: Past and future of biliary atresia. J Pediatr Surg 2000, 35: 717-720.
9. Kuroda T, Saeki M, Nakano M, Morikawa N: Biliary atresia, the next generation: A review of liver function, social activity, and sexual development in the late postoperative period. J Pediatr Surg 2002, 37: 1709-1712.
10. Kuroda T, Saeki M, Morikawa N, Watanabe K: Management of adult biliary atresia patients: Should hard work and pregnancy be discouraged? J Pediatr Surg 2007, 42: 2106-2109.
11. Krantz I, Piccoli D, Spinner N: Alagille syndrome. J Med Genet 1997, 34: 152-157.
12. Emerick K, Rand E, Goldmuntz E, et al.: Features of Alagille syndrome in 92 patients: Frequency and relation to prognosis. Hepatology 1999, 29: 822-829.
13. Tzakis AG, Reyes J, Tepetes K, et al.: Liver transplantation for Alagille's syndrome. Arch Surg 1993, 128: 337-339.
14. Silberbach M, Lashley D, Reller MD, et al.: Arteriohepatic dysplasia and cardiovascular malformations. Am Heart J 1994, 127: 695-699.
15. Fregonese L, Stolk J: Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008, 3: 16.
16. Hansen K, Horslen S: Metabolic liver disease in children. Liver Transpl 2008, 14: 713-733.
17. Taddei T, Mistry P, Schilsky M: Inherited metabolic disease of the liver. Curr Opin Gastroenterol 2008, 24: 278-286.
18. Baranov A, Kaganov B, Gundobina O, Zainudinov Z: Autoimmune hepatitis in children. Int Pediatr 2003, 18: 23-29.
19. Bellomo-Brandão MA, Costa-Pinto EA, De Tommaso AM, Hessel G: Clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients. Arq Gastroenterol 2006, 43: 45-49.
20. Strassburg CP, Manns MP: Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002, 22: 339-352.
21. Czaja A, Freese D: Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36: 479-496.
22. Vergani D, Mieli-Vergani G: Autoimmune liver disease. In Pediatric Gastrointestinal Disease, edn 4. Edited by Walker WA, Goulet O, Kleinman RE. Hamilton, Ontario: BC Decker; 2004:1208-1218.
23. Sartorio A, Del Col A, Agosti F, et al.: Predictors of nonalcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007, 61: 877-883.
24. Kerkar N: Non-alcoholic steatohepatitis in children. Pediatr Transpl 2004, 8: 613-618.
25. Schwimmer J, Behling C, Newbury R, et al.: Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42: 641-649.
26. Marchesini G, Brizi M, Morselli-Labate AM, et al.: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107: 450-455.
27. Nobili V, MarAellini M, Devito R, et al.: NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44: 458-465.
28. Nobili V, Manco M, Ciampalini P, et al.: Metformin use in children with nonalcoholic fatty liver disease: An openlabel, 24 month, observational pilot study. Clin Ther 2008, 30: 1168-1176.
29. Nobili V, Manco M, Devito R, et al.: Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008, 48: 119-127.
30. Ahmed M, Byrne C: Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2008 Jun 16 (Epub ahead of print).
31. Bull LN, Carlton VE, Stricker NL, et al.: Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity. Hepatology 1997, 26: 155-164.
32. Aydogdu S, Cakir M, Arikan C, et al.: Liver transplantation for progressive familial intrahepatic cholestasis: Clinical and histopathological findings, outcome and impact on growth. Pediatr Transpl 2007, 11: 634-640.
33. Leonis M, Balisteri W: Evaluation and management of end-stage liver disease in children. Gastroenterology 2008, 134: 1741-1751.
34. Hurtado-Lopez E, Larrosa-Haro A, Vasquez-Garibay E, et al.: Liver function test results predict nutritional status evaluated by arm anthropometric indicators. J Pediatr Gastroenterol Nutr 2007, 45: 451-457.
35. Scheenstra R, Gerver W, Odink R, et al.: Growth and final height after liver transplantation during childhood. J Pediatr Gastroenterol Nutr 2008, 47: 165-171.
36. Bucuvalas JC, Horn JA, Chernausek SD: Resistance to growth hormone in children with chronic liver disease. Pediatr Transpl 1997, 1: 73-79.
37. Bockhold K, Riely C, Jeffreys C: Overcoming obstacles to immunization in patients with chronic liver disease. Am J Med 2005, 118(Suppl 10A): 40S-45S.
38. Neuhaus T: Immunization in children with chroniA renal failure: a practical approach. Pediatr Nephrol 2004, 19: 1334-1339.
39. Collier J: Bone disorders in chronic liver disease. Hepatology 2007, 46: 1271-1278.